Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation therapy targets tough lung cancer tumors

NCT ID NCT07500285

Disease control Sponsor: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called Y-90 FAPI for people with advanced non-small cell lung cancer that has stopped responding to standard therapies. The treatment delivers radiation directly to cancer cells by targeting a protein found on tumor-supporting cells. The goal is to see if it is safe and can shrink tumors or slow disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) * Metastatic disease * Prior staging with F-18 FDG PET/CT * Ga-68 FAPI PET/CT demonstrating increased tracer uptake in tumor lesions (SUVmax ≥10 in more than 50% of metastatic lesions) * Disease progression or resistance after all standard approved therapies as determined by a multidisciplinary tumor board * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate organ function: * Serum creatinine ≤150 μmol/L * Hemoglobin ≥8.0 g/dL * White blood cell count ≥2.0 × 10⁹/L * Platelet count ≥50 × 10⁹/L * Total bilirubin ≤3 × upper limit of normal * Serum albumin ≥2.0 g/dL * Ability to understand and willingness to sign written informed consent Exclusion Criteria: * Age \<18 years * Diagnosis of small cell lung cancer * History of another active malignancy * Pregnancy or breastfeeding * Severe uncontrolled medical illness that would interfere with study participation * Refusal or inability to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic lung carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm metastatic carcinoma metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic lung carcinoma Non small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Prof. Dr. Cemil Taşcıoğlu City Hospital

    Istanbul, 34384, Turkey (Türkiye)

  • Prof. Dr. Cemil Taşçıoğlu City Hospital

    Istanbul, 34384, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.